Baxter Signs Definitive Agreement to Divest its BioPharma Solutions Business to Advent International and Warburg Pincus for $4.25 Billion
Digital Health Global
MAY 8, 2023
The transaction is expected to close in the second half of 2023, subject to receipt of customary regulatory approvals and satisfaction of other customary closing conditions. For the full fourth quarter 2023, Baxter estimates the transaction to result in dilution of approximately $0.10
Let's personalize your content